LAUSR

Since December 2019, there has been an increasing number of unexplained cases of pneumonia in Wuhan, a city with 11 million people in China’s Hubei province, which quickly spread to other cities and also abroad. These cases with laboratory confirmed a viral infection have been detected in the world and the World Health Organization (WHO) called this virus as COVID-19 .Given the rapid spread and high mortality rate of COVID-19 with acute kidney injury (AKI), it is absolutely necessary to evaluate the clinical characteristics and possible risk factors affecting the progression of disease in COVID-19 patients with AKI. The clinical data of COVID-19 patients from 1 December 2019 to 30 June 2020 were retrieved from databases, including PubMed, Embase, Web of Science, WanFang Data, CNKI, and medrxiv. We statistically analyzed the clinical characteristics, symptoms and examination s results of COVID-19 patients and explained the clinical features of a meta-analysis. The available data of 789 patients in four publications were included in our meta-analysis [1–4]. The common clinical symptoms of COVID-19 patients with AKI were fever, cough, myalgia or fatigue which is the same as COVID-19 patients with non-AKI (NAKI). But what s more common than general COVID-19s than the patients with AKI was hypoxia. The results of laboratory results showed that the COVID-19 patients with AKI had higher procalcitonine besides increased lymphocytopenia, C-reactive protein (CRP), lactate dehydrogenase (LDH) and leukocytopenia that represented more inflammation. Meanwhile our metaanalysis found the male with underlying disease like diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular or cardiovascular disease were more likely to get AKI. As we can see those patients were also more likely to have lower discharge rate and higher fatality rate. Figure 1. A flow diagram of the inclusion criteria of studies eligible for meta-analysis.